14 October 2026
14 October 2026
Despite several products succumbing to generics and biosimilars, J&J raised its 2026 guidance.
The new strategy focuses on making the MHRA’s drug and device regulation more efficient and patient centric with the use of technologies like AI.
Enodia Therapeutics will handle initial discovery work to identify, refine, and advance small-molecule candidates directed at multiple targets.
The pharma-backed company will now progress three drugs for FSHD, heart failure and muscle & metabolic disorders to the clinic.
The partnership focuses on biologics quality control as well as viral and release testing under cGMP standards.
The Swiss pharma giant now joins a growing list of big pharma and biotech players exploring the RNAi approach’s promise in treating obesity.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
